SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

MW005

MDWD·MediWound Ltd.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/2 (completed)
Time to market
Years away. MW005 has completed Phase 1/2 testing but has no disclosed Phase 2/3 trial start or regulatory pathway, making any timeline to potential approval speculative and likely several years off if development proceeds.
Why 2/10
MW005 has no hard dated catalyst (PDUFA, pivotal readout, or Advisory Committee) scheduled in the next 12 months. The Phase 1/2 study concluded in 2023 with positive results, but no next-phase trial start or regulatory milestone has been announced. The drug is a small part of MediWound's pipeline behind commercial NexoBrid and Phase 3 EscharEx, so impactScore is low.
Actionable Insight NEUTRAL

MW005 has no scheduled regulatory or pivotal-readout catalyst in the next 12 months. The next company-wide event is Q3 2026 earnings on November 12, 2026, but that is a financial update, not a drug-specific binary. Watch for any announcement from MediWound on next-phase development plans for MW005, which would be the first signal of meaningful pipeline progression.

Price Chart

Loading chart...

Executive Summary

MW005 is a topical biologic gel in development by MediWound Ltd. (Nasdaq: MDWD) for low-risk Basal Cell Carcinoma (BCC), the most common form of skin cancer. It uses proteolytic enzymes (bromelain from pineapple stems) to digest cancerous tissue, offering a potential non-surgical alternative to excision. A Phase 1/2 study completed in 2023 showed positive results with complete clinical and histological clearance of target lesions and a good safety profile. However, MW005 is an early-stage asset with no disclosed next-phase trial or regulatory milestone, and it is a small part of MediWound's pipeline behind the approved NexoBrid burn treatment and the Phase 3 EscharEx wound-care program. The stock recently completed a $17.25M offering at $12.50/share and trades at $13.33, with analysts bullish (mean target $30.67) but primarily on the company's core burn/wound franchise rather than MW005 specifically.

How It Works

MW005 is a topical gel containing a concentrated mixture of protein-digesting enzymes (proteolytic enzymes) derived from pineapple stems, primarily bromelain. When applied directly to basal cell carcinoma lesions on the skin, these enzymes break down the proteins that make up the cancerous tissue, selectively removing it while preserving healthy surrounding skin. The drug is designed for patients to apply themselves at home as a non-surgical alternative to cutting out skin cancer lesions.

Trial Status

A Phase 1/2 open-label, multicenter, randomized trial in low-risk BCC completed with positive results announced July 2023. Patients received seven topical applications over 14 days; eight weeks later target lesions were surgically removed and assessed. The drug was safe, well-tolerated, and achieved complete clinical and histological clearance. An investigator-initiated Phase 2 trial for non-melanoma skin cancers (including BCC, squamous cell carcinoma, actinic keratosis) was also conducted at Soroka Medical Center in Israel, but no results have been publicly reported. No further clinical trials have been announced since.

The Two-Sided Case

▲ Bull Case3
Phase 1/2 data showed MW005 was safe, well-tolerated, and achieved complete clinical and histological clearance of target lesions in low-risk BCC patients, offering a potential non-surgical topical alternative to excision.
MW005 shares the same active pharmaceutical ingredient (proteolytic enzymes enriched in bromelain) as MediWound's approved product NexoBrid, leveraging an established platform with regulatory precedent.
Analyst consensus on MDWD is bullish: 8 Buy, 3 Strong Buy, 1 Hold, 0 Sell, with a mean price target of $30.67 (approximately 130% implied upside from the $13.33 close).
▼ Bear Case3
MW005 is an early-stage (Phase 1/2 completed) asset with no disclosed next-phase trial initiation or regulatory path, making its timeline to commercialization uncertain and likely years away.
MediWound's primary pipeline focus and capital allocation is on the EscharEx Phase 3 VALUE trial and its commercial NexoBrid business, leaving MW005 as a lower-priority pipeline asset with limited near-term value inflection.
The company completed a $17.25M stock offering on November 5, 2026, diluting existing shareholders, and the stock fell 6.1% on the day to $13.33, well below the mean analyst target of $30.67.

Upcoming Catalysts

  • No scheduled drug-specific catalyst for MW005 identified. The next company-wide event is Q3 2026 earnings on November 12, 2026, which may include pipeline updates.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

MediWound Ltd. 424B5 MDWD ·Originating report

Sources · 7

Hover a chip for the title
1 biospace.com2 pryzm.ozmosi.com3 synapse.patsnap.com4 mediwound.gcs-web.com5 marketscreener.com6 nasdaq.com7 mediwound.com